Discounted Cash Flow
Neurocrine Biosciences Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $15.0m | $-141.1m | $-110.3m | -940.6% | $-1.63 |
| 2017 | $161.6m (977.5%) | $-142.5m (-1.0%) | $-101.3m (8.2%) | -88.2% (90.6%) | $-1.62 (0.6%) |
| 2018 | $451.2m (179.2%) | $21.1m (114.8%) | $76.6m (175.6%) | 4.7% (105.3%) | $0.23 (114.2%) |
| 2019 | $788.1m (74.6%) | $37.0m (75.3%) | $137.3m (79.4%) | 4.7% (0.4%) | $0.40 (73.9%) |
| 2020 | $1.0b (32.7%) | $407.3m (1000.5%) | $217.6m (58.5%) | 38.9% (729.2%) | $4.38 (995.0%) |
| 2021 | $1.1b (8.4%) | $89.6m (-78.0%) | $233.1m (7.1%) | 7.9% (-79.7%) | $0.95 (-78.3%) |
| 2022 | $1.5b (31.3%) | $154.5m (72.4%) | $322.9m (38.5%) | 10.4% (31.3%) | $1.61 (69.5%) |
| 2023 | $1.9b (26.8%) | $249.7m (61.6%) | $361.6m (12.0%) | 13.2% (27.5%) | $2.56 (59.0%) |
| 2024 | $2.4b (24.8%) | $341.3m (36.7%) | $557.2m (54.1%) | 14.5% (9.5%) | $3.40 (32.8%) |
| 2025 | $2.9b (21.4%) | $478.6m (40.2%) | $748.7m (34.4%) | 16.7% (15.5%) | $4.81 (41.5%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.